Dr. Sumanta K. Pal
Claim this profileCity of Hope Medical Center
Expert in Skin Cancer
Studies Kidney Cancer
15 reported clinical trials
21 drugs studied
Area of expertise
1Skin Cancer
Global LeaderStage IV
Stage III
2Kidney Cancer
Stage IV
RECIST 1.1
metastatic
Affiliated Hospitals
Clinical Trials Sumanta K. Pal is currently running
Radioactive Drug Therapy
for Prostate Cancer
This trial studies how well lutetium Lu 177 dotatate works in treating patients with a specific type of prostate cancer that has spread. The drug targets cancer cells and releases radiation to kill them. Lutetium-177 (Lu-177) PSMA therapy is a targeted treatment for advanced prostate cancer that has shown promising results.
Recruiting1 award Phase 216 criteria
Cabozantinib +/− Atezolizumab
for Advanced Kidney Cancer
This phase II trial compares the effect of atezolizumab in combination with usual treatment with cabozantinib to cabozantinib alone in patients with papillary renal cell carcinoma that has spread to other places in the body (metastatic). Papillary renal cell carcinoma (PRCC) is a type of kidney cancer that forms in the lining of the tiny tubes in the kidney that return filtered substances that the body needs back to the blood and remove extra fluid and waste as urine. Most papillary tumors look like long, thin finger-like growths under a microscope. It is also called papillary kidney cancer or PRCC. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help body's immune system attack the cancer and may interfere with the ability of tumor cells to grow and spread. Cabozantinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply and may also prevent the growth of new blood vessels that tumors need to grow. By these actions it may help slow or stop the spread of cancer cells. Combination therapy with atezolizumab and cabozantinib may shrink the cancer and allow a longer survival time in patients with metastatic renal cell carcinoma.
Recruiting1 award Phase 230 criteria
More about Sumanta K. Pal
Clinical Trial Related8 years of experience running clinical trials · Led 15 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Sumanta K. Pal has experience with
- Nivolumab
- Ipilimumab
- Cabozantinib S-malate
- Clostridium Butyricum CBM 588 Probiotic Strain
- Pembrolizumab
- Atezolizumab
Breakdown of trials Sumanta K. Pal has run
Skin Cancer
Kidney Cancer
Renal Cell Carcinoma
Bladder Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Sumanta K. Pal specialize in?
Sumanta K. Pal focuses on Skin Cancer and Kidney Cancer. In particular, much of their work with Skin Cancer has involved Stage IV patients, or patients who are Stage III.
Is Sumanta K. Pal currently recruiting for clinical trials?
Yes, Sumanta K. Pal is currently recruiting for 3 clinical trials in Duarte California. If you're interested in participating, you should apply.
Are there any treatments that Sumanta K. Pal has studied deeply?
Yes, Sumanta K. Pal has studied treatments such as Nivolumab, Ipilimumab, Cabozantinib S-malate.
What is the best way to schedule an appointment with Sumanta K. Pal?
Apply for one of the trials that Sumanta K. Pal is conducting.
What is the office address of Sumanta K. Pal?
The office of Sumanta K. Pal is located at: City of Hope Medical Center, Duarte, California 91010 United States. This is the address for their practice at the City of Hope Medical Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.